Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: GlobeNewswire
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine in a new Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant treatment effects of blarcamesine were detected using both a test of impaired motor function and a biomarker of dopaminergic nerve fiber density, indicating fiber r
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Touts Oral Alzheimer's Drug Blarcamesine Data, Cash Runway at Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences to Present at the Citizens Life Sciences ConferenceGlobeNewswire
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care ConferenceGlobeNewswire
AVXL
Earnings
- 2/9/26 - Beat
AVXL
Sec Filings
- 2/25/26 - Form 8-K
- 2/9/26 - Form 10-Q
- 2/9/26 - Form 8-K
- AVXL's page on the SEC website